Ignite Creation Date:
2025-12-24 @ 10:04 PM
Ignite Modification Date:
2025-12-28 @ 11:45 AM
Study NCT ID:
NCT06143735
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-22
First Post:
2023-11-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-16
First Submit QC Date:
None
Study First Post Date:
2023-11-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-16
Last Update Post Date:
2023-11-22
Last Update Post Date Type:
ACTUAL